Published in Biomed Res Int on April 13, 2014
Inflammation in Parkinson's disease: role of glucocorticoids. Front Neuroanat (2015) 0.95
The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med (2015) 0.94
Converging mediators from immune and trophic pathways to identify Parkinson disease dementia. Neurol Neuroimmunol Neuroinflamm (2016) 0.84
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation (2015) 0.84
Plant-derived neuroprotective agents in Parkinson's disease. Am J Transl Res (2015) 0.81
Inhibition of Calpain Activation Protects MPTP-Induced Nigral and Spinal Cord Neurodegeneration, Reduces Inflammation, and Improves Gait Dynamics in Mice. Mol Neurobiol (2015) 0.81
LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals. Curr Neuropharmacol (2016) 0.80
Effect of Ixeris dentata Nakai Extract on Nitric Oxide Production and Prostaglandin E2 Generation in LPS-stimulated RAW264.7 Cells. Immune Netw (2015) 0.78
Inhibitory Effects of JEUD-38, a New Sesquiterpene Lactone from Inula japonica Thunb, on LPS-Induced iNOS Expression in RAW264.7 Cells. Inflammation (2015) 0.77
LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives. Clin Pharmacol (2016) 0.76
The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach. Nucl Med Biol (2015) 0.76
Splicing Regulation of Pro-Inflammatory Cytokines and Chemokines: At the Interface of the Neuroendocrine and Immune Systems. Biomolecules (2015) 0.75
A Novel Immunosuppressor, (5R)-5-Hydroxytriptolide, Alleviates Movement Disorder and Neuroinflammation in a 6-OHDA Hemiparkinsonian Rat Model. Aging Dis (2017) 0.75
Sodium thiosulphate attenuates brain inflammation induced by systemic lipopolysaccharide administration in C57BL/6J mice. Inflammopharmacology (2017) 0.75
Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's Disease. Front Neurosci (2017) 0.75
The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved? Metab Brain Dis (2017) 0.75
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell (2006) 19.16
Inflammation and insulin resistance. J Clin Invest (2006) 18.76
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci (2006) 12.23
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci (2007) 11.24
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med (2005) 10.88
The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron (2008) 10.19
Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell (2006) 10.18
The inflammatory reflex. Nature (2002) 9.10
Adipose tissue, inflammation, and cardiovascular disease. Circ Res (2005) 8.72
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79
Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 4.88
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology (2005) 4.35
Prostaglandins as modulators of immunity. Trends Immunol (2002) 4.15
Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci (2005) 3.93
Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J (2005) 3.84
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav Immun (2007) 3.07
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology (2006) 3.01
Increased number of islet-associated macrophages in type 2 diabetes. Diabetes (2007) 3.01
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest (1996) 2.73
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis (2005) 2.59
Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep (2006) 2.54
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci (2007) 2.39
Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun (2008) 2.37
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 2.27
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17
Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci (1993) 2.16
mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol Aging (2006) 2.06
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
Astrocyte intermediate filaments in CNS pathologies and regeneration. J Pathol (2004) 1.87
Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci (2003) 1.87
Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci (2008) 1.85
Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimers Dement (2007) 1.82
The age-related attenuation in long-term potentiation is associated with microglial activation. J Neurochem (2006) 1.76
A timeline for Parkinson's disease. Parkinsonism Relat Disord (2009) 1.75
Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol (2007) 1.74
Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway. J Biol Chem (2005) 1.70
Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun (2008) 1.70
In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord (2002) 1.68
Altered antigen expression of microglia in the aged rodent CNS. Glia (1993) 1.68
Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett (1996) 1.64
Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology (2009) 1.64
Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging (2007) 1.63
LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci (2012) 1.61
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci (1999) 1.58
An age-related decline in interleukin-10 may contribute to the increased expression of interleukin-6 in brain of aged mice. Neuroimmunomodulation (2001) 1.55
Microglial expression of MHC class II increases in normal aging of nonhuman primates. Neurobiol Aging (1998) 1.54
Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem (1998) 1.52
Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol (1998) 1.47
LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol (2006) 1.46
Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging (2010) 1.45
Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J Appl Physiol (1985) (2006) 1.45
Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci (2012) 1.44
Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord (2009) 1.43
Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci (2011) 1.42
Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol (2008) 1.40
Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord (2012) 1.38
Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Front Biosci (2003) 1.35
Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally. Exp Neurol (2004) 1.34
Innate immune receptor expression in normal brain aging. Neuroscience (2007) 1.34
AMP-activated protein kinase-regulated activation of the PGC-1alpha promoter in skeletal muscle cells. PLoS One (2008) 1.32
LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener (2012) 1.32
Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. J Neurosci Res (2002) 1.32
PPARdelta, but not PPARalpha, activates PGC-1alpha gene transcription in muscle. Biochem Biophys Res Commun (2007) 1.32
GFAP mRNA increases with age in rat and human brain. Neurobiol Aging (1994) 1.31
Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect (2011) 1.30
Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation (2007) 1.30
Cytokines in Parkinson's disease. J Neural Transm Suppl (2000) 1.27
Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol (2009) 1.27
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord (2006) 1.27
Prospects for minocycline neuroprotection. Arch Neurol (2010) 1.27
Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem (2009) 1.24
Blood-brain barrier alterations in ageing and dementia. J Neurol Sci (2009) 1.24
Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One (2012) 1.21
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
Inflammatory processes in the aging mouse brain: participation of dendritic cells and T-cells. Neurobiol Aging (2006) 1.20
Downregulation of IL-4-induced signalling in hippocampus contributes to deficits in LTP in the aged rat. Neurobiol Aging (2005) 1.16
Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One (2011) 1.15
Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. J Proteome Res (2009) 1.13
Long-term survival of Parkinson's disease: a population-based study. J Neurol (2005) 1.13
Causes of death in a community-based study of Parkinson's disease. Acta Neurol Scand (2001) 1.11
Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience (2012) 1.11
Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson`s disease. J Neurochem (2010) 1.11
Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol (2009) 1.09
Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res (2009) 1.08
A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease. Hum Mol Genet (2013) 1.07
Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm (Vienna) (2004) 1.06
Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm (Vienna) (2000) 1.06
Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Exp Neurol (2003) 1.06
Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen. Biochem Biophys Res Commun (2010) 1.06
Rosiglitazone-induced mitochondrial biogenesis in white adipose tissue is independent of peroxisome proliferator-activated receptor γ coactivator-1α. PLoS One (2011) 1.05
Colonic inflammation in Parkinson's disease. Neurobiol Dis (2012) 1.04
The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease. Psychosomatics (2010) 1.03